Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
Abstract We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.4111 |